TBG Diagnostics Limited reported unaudited consolidated earnings results for the year ended December 31, 2017. For the year, the company reported net loss attributable to equity holders of the company of AUD 6,540,390 or 3.0 cents per basic and diluted share compared to net loss attributable to equity holders of the company of AUD 2,621,085 or 1.2 cents per basic and diluted share reported in the comparative six months period ended December 31, 2016. Loss from continuing operations was AUD 3,860,046 or 1.8 cents per basic and diluted share against AUD 2,805,738 or 1.1 cents per basic and diluted share reported in the comparative six months period ended December 31, 2016. Revenue from continuing operations was AUD 4,024,804 against AUD 1,351,713 reported in the comparative six months period ended December 31, 2016. Loss from continuing operations before tax was AUD 3,860,046 against AUD 2,805,738 reported in the comparative six months period ended December 31, 2016. Net cash outflow from operating activities was AUD 2,433,765 against AUD 2,777,256 reported in the comparative six months period ended December 31, 2016. Payments for property, plant and equipment were AUD 426,990 against AUD 110,154 reported in the comparative six months period ended December 31, 2016. The company changed its financial year from 30 June to 31 December. As a result, the financial period that is the subject of this Financial Report is the twelve-month period from 1 January 2017 to 31 December 2017. The comparative period is for the six-month period from 1 July 2016 to 31 December 2016.